Electra Therapeutics closed a $183 million Series C to advance its lead SIRP‑targeting program ELA026 into pivotal testing for secondary hemophagocytic lymphohistiocytosis and to support additional pipeline assets. The round was co-led by Nextech and EQT Life Sciences and drew strategic participation from Sanofi and institutional investors. Company leadership framed the financing as validation of Electra’s mechanism and a ticket to global development scale-up.